First oral GLP-1RA approved in the US

News - Oct. 2, 2019

The US FDA has approved semaglutide tablets as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Oral semaglutide is the first approved glucagon-like peptide-1 (GLP-1) receptor agonist in a tablet, is an analogue of the naturally occurring hormone GLP-1. It is administered once daily and is approved for use in two therapeutic dosages, 7 mg and 14 mg.

Approval of oral semaglutide is based on the results from 10 PIONEER clinical trials which included 9,543 adults with type 2 diabetes. Oral semaglutide more effectively lowered blood sugar than sitagliptin and empagliflozin. Furthermore, treatment with oral semaglutide resulted in up to 4.4 kg reduction in body weight. Oral semaglutide demonstrated a safe and well-tolerated profile across the PIONEER programme, with the most common adverse event being mild to moderate nausea, which diminished over time.

Source: press release Novo Nordisk September 20, 2019 Read about the results of the recent PIONEER 2 and 8 trials

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free